Transtorno de deficit da atenção com hiperatividade em adultos

Referências

Principais artigos

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. September 2019 [internet publication].Texto completo

Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818.Texto completo  Resumo

Artigos de referência

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. (DSM-5). Washington, DC: American Psychiatric Publishing; 2013.

3. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. September 2019 [internet publication].Texto completo

4. Kates N. Attention deficit disorder in adults. Management in primary care. Can Fam Physician. 2005 Jan;51(1):53-9.Texto completo  Resumo

5. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006 Apr;163(4):716-23.Texto completo  Resumo

6. Rollini M, Baud P. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults [in French]. Rev Med Suisse. 2008 Jul 16;4(165):1638-43. Resumo

7. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007 May;190:402-9.Texto completo  Resumo

8. Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J Atten Disord. 2005 Nov;9(2):384-91. Resumo

9. Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009 Mar;194(3):204-11.Texto completo  Resumo

10. Brugha T, Asherson P, Strydom A, et al. Adult psychiatric morbidity survey 2014, chapter 8: attention-deficit/ hyperactivity disorder. 2014 [internet publication].Texto completo

11. Chung W, Jiang SF, Paksarian D, et al. Trends in the prevalence and incidence of attention-deficit/hyperactivity disorder among adults and children of different racial and ethnic groups. JAMA Netw Open. 2019 Nov 1;2(11):e1914344.Texto completo  Resumo

12. Ghirardi L, Brikell I, Kuja-Halkola R, et al. The familial co-aggregation of ASD and ADHD: a register-based cohort study. Mol Psychiatry. 2018 Feb;23(2):257-62.Texto completo  Resumo

13. Wingo AP, Ghaemi SN. A systematic review of rates and diagnostic validity of comorbid adult attention-deficit/hyperactivity disorder and bipolar disorder. J Clin Psychiatry. 2007 Nov;68(11):1776-84. Resumo

14. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008 Dec;65(12):835-42.Texto completo  Resumo

15. Ramtekkar UP, Reiersen AM, Todorov AA, et al. Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11. J Am Acad Child Adolesc Psychiatry. 2010 Mar;49(3):217-28.Texto completo  Resumo

16. Cortese S, Moreira-Maia CR, St Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry. 2016 Jan;173(1):34-43.Texto completo  Resumo

17. Wilens TE, Faraone SV, Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA. 2004 Aug 4;292(5):619-23. Resumo

18. Haberstick BC, Timberlake D, Hopfer CJ, et al. Genetic and environmental contributions to retrospectively reported DSM-IV childhood attention deficit hyperactivity disorder. Psychol Med. 2008 Jul;38(7):1057-66. Resumo

19. Schultz MR, Rabi K, Faraone SV, et al. Efficacy of retrospective recall of attention-deficit hyperactivity disorder symptoms: a twin study. Twin Res Hum Genet. 2006 Apr;9(2):220-32. Resumo

20. van den Berg SM, Willemsen G, de Geus EJ, et al. Genetic etiology of stability of attention problems in young adulthood. Am J Med Genet B Neuropsychiatr Genet. 2006 Jan 5;141B(1):55-60. Resumo

21. Halperin JM, Trampush JW, Miller CJ, et al. Neuropsychological outcome in adolescents/young adults with childhood ADHD: profiles of persisters, remitters and controls. J Child Psychol Psychiatry. 2008 Sep;49(9):958-66.Texto completo  Resumo

22. Faraone SV, Banaschewski T, Coghill D, et al. The World Federation of ADHD International Consensus Statement: 208 evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818.Texto completo  Resumo

23. Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet. 2010 Oct 23;376(9750):1401-8.Texto completo  Resumo

24. Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019 Jan;51(1):63-75.Texto completo  Resumo

25. Retz W, Rosler M, Kissling C, et al. Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. J Neural Transm (Vienna). 2008;115(2):323-9. Resumo

26. Stevens SE, Sonuga-Barke EJ, Kreppner JM, et al. Inattention/overactivity following early severe institutional deprivation: presentation and associations in early adolescence. J Abnorm Child Psychol. 2008 Apr;36(3):385-98. Resumo

27. Buschgens CJ, van Aken MA, Swinkels SH, et al. Differential family and peer environmental factors are related to severity and comorbidity in children with ADHD. J Neural Transm (Vienna). 2008;115(2):177-86. Resumo

28. Man KK, Chan EW, Ip P, et al. Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study. BMJ. 2017 May 31;357:j2350.Texto completo  Resumo

29. Christensen J, Pedersen L, Sun Y, et al. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring.JAMA Netw Open. 2019 Jan 4;2(1):e186606.Texto completo  Resumo

30. Zametkin AJ, Nordahl TE, Gross M, et al. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med. 1990 Nov 15;323(20):1361-6.Texto completo  Resumo

31. Amen DG, Hanks C, Prunella J. Preliminary evidence differentiating ADHD using brain SPECT imaging in older patients. J Psychoactive Drugs. 2008 Jun;40(2):139-46. Resumo

32. Poelmans G, Pauls DL, Buitelaar JK, et al. Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am J Psychiatry. 2011 Apr;168(4):365-77.Texto completo  Resumo

33. Kinsbourne M. Minimal brain dysfunction as a neurodevelopmental lag. Ann N Y Acad Sci. 1973 Feb 28;205:268-73. Resumo

34. Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19649-54.Texto completo  Resumo

35. Dias G, Mattos P, Coutinho G, et al. Agreement rates between parent and self-report on past ADHD symptoms in an adult clinical sample. J Atten Disord. 2008 Jul;12(1):70-5. Resumo

36. Youssef NA, Ege M, Angly SS, et al. Is obstructive sleep apnea associated with ADHD? Ann Clin Psychiatry. 2011 Aug;23(3):213-24. Resumo

37. Crunelle CL, van den Brink W, Moggi F, et al. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur Addict Res. 2018;24(1):43-51.Texto completo  Resumo

38. Wilens TE. The nature of the relationship between attention-deficit/hyperactivity disorder and substance use. J Clin Psychiatry. 2007;68 (Suppl 11):4-8. Resumo

39. Fischer M, Barkley RA, Smallish L, et al. Hyperactive children as young adults: driving abilities, safe driving behavior, and adverse driving outcomes. Accid Anal Prev. 2007 Jan;39(1):94-105. Resumo

40. Mannuzza S, Klein RG, Moulton JL 3rd. Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Res. 2008 Sep 30;160(3):237-46.Texto completo  Resumo

41. DuPaul GJ, Stoner G. ADHD in the schools: assessment and intervention strategies. New York, NY: Guilford Press; 1994.

42. Kessler RC, Adler LA, Gruber MJ, et al. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res. 2007;16(2):52-65.Texto completo  Resumo

43. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999 Oct;46(5):857-70. Resumo

44. Audenaert K, Jansen HM, Otte A, et al. Imaging of mild traumatic brain injury using 57Co and 99mTc HMPAO SPECT as compared to other diagnostic procedures. Med Sci Monit. 2003 Oct;9(10):MT112-7.Texto completo  Resumo

45. World Health Organization. ICD-11 International statistical classification of diseases and related health problems, 11th revision Geneva: WHO; 2022.Texto completo

46. Barkley RA, ed. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3rd ed. New York, NY: Guilford Press; 2006.

47. Brown TE. The Brown attention deficit disorder scales. San Antonio, TX: Psychological Corporation; 1996.

48. Wender PH. Attention-deficit hyperactivity disorder in adults. New York, NY: Oxford University Press; 2001.

49. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993 Jun;150(6):885-90. Resumo

50. Das D, Vélez JI, Acosta MT, et al. Retrospective assessment of childhood ADHD symptoms for diagnosis in adults: validity of a short 8-item version of the Wender-Utah Rating Scale. Atten Defic Hyperact Disord. 2016 Dec;8(4):215-23. Resumo

51. Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am Fam Physician. 2000 Nov 1;62(9):2077-86.Texto completo  Resumo

52. Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS Spectr. 2008 Nov;13(11):977-84. Resumo

53. Taylor A, Deb S, Unwin G. Scales for the identification of adults with attention deficit hyperactivity disorder (ADHD): a systematic review. Res Dev Disabil. 2011 May-Jun;32(3):924-38. Resumo

54. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-38.Texto completo  Resumo

55. Spencer TJ, Adler LA, Meihua Qiao, et al. Validation of the adult ADHD investigator symptom rating scale (AISRS). J Atten Disord. 2010 Jul;14(1):57-68. Resumo

56. Moran LV, Ongur D, Hsu J, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019 Mar 21;380(12):1128-38.Texto completo  Resumo

57. Hollis C, Chen Q, Chang Z, et al. Methylphenidate and the risk of psychosis in adolescents and young adults: a population-based cohort study. Lancet Psychiatry. 2019 Aug;6(8):651-8.Texto completo  Resumo

58. Hodgkins P, Shaw M, McCarthy S, et al. The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter? CNS Drugs. 2012 Mar 1;26(3):245-68. Resumo

59. Schneider-Thoma J, Efthimiou O, Bighelli I, et al. Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. Lancet Psychiatry. 2019 Sep;6(9):753-65. Resumo

60. Verbeeck W, Bekkering GE, Van den Noortgate W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017 Oct 2;(10):CD009504.Texto completo  Resumo

61. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2010 Jun;71(6):754-63. Resumo

62. Kendall T, Taylor E, Perez A, et al; Guideline Development Group. Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. BMJ. 2008 Sep 24;337:a1239. Resumo

63. Young Z, Moghaddam N, Tickle A. The efficacy of cognitive behavioral therapy for adults with ADHD: a systematic review and meta-analysis of randomized controlled trials. J Atten Disord. 2020 Apr;24(6):875-88.Texto completo  Resumo

64. Lopez PL, Torrente FM, Ciapponi A, et al. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018 Mar 23;(3):CD010840.Texto completo  Resumo

65. Emilsson B, Gudjonsson G, Sigurdsson JF, et al. Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC Psychiatry. 2011 Jul 25;11:116.Texto completo  Resumo

66. Knouse LE, Safren SA. Current status of cognitive behavioral therapy for adult attention-deficit hyperactivity disorder. Psychiatr Clin North Am. 2010 Sep;33(3):497-509.Texto completo  Resumo

67. Solanto MV, Marks DJ, Wasserstein J, et al. Efficacy of meta-cognitive therapy for adult ADHD. Am J Psychiatry. 2010 Aug;167(8):958-68.Texto completo  Resumo

68. Hirvikoski T, Waaler E, Alfredsson J, et al. Reduced ADHD symptoms in adults with ADHD after structured skills training group: results from a randomized controlled trial. Behav Res Ther. 2011 Mar;49(3):175-85. Resumo

69. Adamou M, Asherson P, Arif M, et al. Recommendations for occupational therapy interventions for adults with ADHD: a consensus statement from the UK adult ADHD network. BMC Psychiatry. 2021 Feb 4;21(1):72.Texto completo  Resumo

70. Katzman MA, Bilkey TS, Chokka PR, et al. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017 Aug 22;17(1):302.Texto completo  Resumo

71. Boesen K, Paludan-Müller AS, Gøtzsche PC, et al. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2022 Feb 24;2:CD012857.Texto completo  Resumo

72. American Psychiatric Association. Guideline watch (March 2013): Practice guideline for the treatment of patients with obsessive-compulsive disorderTexto completo

73. Pompoli A, Furukawa TA, Imai H, et al. Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. Cochrane Database Syst Rev. 2016 Apr 13;4:CD011004.Texto completo  Resumo

74. Rodrigues MF, Nardi AE, Levitan M. Mindfulness in mood and anxiety disorders: a review of the literature. Trends Psychiatry Psychother. 2017 Jul-Sep;39(3):207-15.Texto completo  Resumo

75. Nasser A, Liranso T, Adewole T, et al. A phase Ill, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit/hyperactivity disorder in school-age children. Clin Ther. 2020 Aug;42(8):1452-66.Texto completo  Resumo

76. Nasser A, Liranso T, Adewole T, et al. A phase 3, placebo-controlled trial of once-daily viloxazine extended-release capsules in adolescents with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2021 Jul-Aug 01;41(4):370-80.Texto completo  Resumo

77. Nasser A, Liranso T, Adewole T, et al. A phase 3 placebo-controlled trial of once-daily 400-mgand 600-mg SPN-812 (viloxazine extended-release) in adolescents with ADHD.Psychopharmacol Bull. 2021 Mar 16;51(2):43-64.Texto completo  Resumo

78. Nasser A, Liranso T, Adewole T, et al. Once-daily SPN-812 200 and 400 mg in the treatment ofADHD in school-aged children: a phase III randomized, controlled trial. Clin Ther. 2021Apr;43(4): 684-700Texto completo  Resumo

79. Lugo J, Fadeuilhe C, Gisbert L, et al. Sleep in adults with autism spectrum disorder and attention deficit/hyperactivity disorder: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2020 Sep;38:1-24.Texto completo  Resumo

80. Septier M, Stordeur C, Zhang J, et al. Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2019 Aug;103:109-18.Texto completo  Resumo

81. Chang Z, Quinn PD, Hur K, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry. 2017 Jun 1;74(6):597-603.Texto completo  Resumo

82. Barkley RA, Cox D. A review of driving risks and impairments associated with attention-deficit/hyperactivity disorder and the effects of stimulant medication on driving performance. J Safety Res. 2007;38(1):113-28. Resumo

83. Jerome L, Habinski L, Segal A. Attention-deficit/hyperactivity disorder (ADHD) and driving risk: a review of the literature and a methodological critique. Curr Psychiatry Rep. 2006 Oct;8(5):416-26. Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal